Cynosure Advisors’s ResMed RMD Stock Holding History

Cynosure Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,896	Closed	-$300K	–	155
2018 Q2	$300K	Hold	2,896	–	–	0.08%	184
2018 Q1	$285K	Buy	2,896 +32	+1%	+$3.02K	0.07%	182
2017 Q4	$243K	Buy	+2,864	New	+$237K	0.06%	204

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cynosure Advisors's RMD Position: Q3 2018 in Review

Cynosure Advisors sold out of ResMed (RMD) in Q3 2018, closing a stake of 2,896 shares — an estimated $300K sold.

Cynosure Advisors first reported a position in RMD in Q4 2017 and held it in 3 quarters. The position peaked at $300K in Q2 2018. 497 funds tracked by Wall St. Rank hold RMD as of Q3 2018.

Cynosure Advisors reported no remaining ResMed position as of Q3 2018 after selling out during the quarter.
Cynosure Advisors sold 2,896 ResMed shares in Q3 2018, an estimated $300K.
Cynosure Advisors first reported a position in ResMed in Q4 2017 and held it in 3 quarters.
Cynosure Advisors's ResMed position peaked at $300K in Q2 2018.
497 funds tracked by Wall St. Rank held ResMed as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.